In a pathology lab, the most valuable piece of evidence is often destroyed in the process of being read. For over a hundred years, the standard has been to slice a tissue sample into thin sections, mount them on glass slides, and stain them for a microscope. That process consumes the specimen, limiting re-analysis and locking away the three-dimensional context of the original tissue. A Berlin-based startup, LIMAA Technologies, is building a platform to change that fundamental workflow, aiming to give pathologists a digital, 3D view of an entire biopsy while keeping the tissue intact for future tests [LIMAA Technologies, retrieved 2026].
The Wedge: A Preserved, Whole-Specimen Workflow
LIMAA’s core proposition is an integrated system that processes, stains, images, and analyzes tissue without ever slicing it. The company combines proprietary chemical reagents, automated sample preparation, light-sheet microscopy, and regulated diagnostic software into what it calls a fully automated, tissue-preserving digital histopathology platform [LIMAA Technologies, retrieved 2026]. The clinical promise is twofold: first, to provide a more complete diagnostic picture by visualizing biomarkers in their native 3D architecture, and second, to preserve the precious tissue sample for downstream applications like genomic sequencing or additional biomarker analysis [LinkedIn, retrieved 2026].
This end-to-end approach is the company’s primary differentiator. It is not selling just a microscope or just an AI image analysis tool, but an entire regulated workflow intended for clinical laboratories. A key component is its library of proprietary nanobodies, tiny antibody fragments it brands as LIMAAbodies®, which are engineered to penetrate whole tissue samples for staining [NANOBODIES-Online, retrieved 2026]. The company has even launched a dedicated web shop for these research reagents, suggesting an early, if niche, revenue stream [Datamintelligence.com, Jun 2024].
A Strategic Foot in the Clinic
For a hardware-and-software medical device startup, a partnership with an operational diagnostic laboratory is a critical validation step. In January 2025, LIMAA announced a strategic development partnership with Labor Becker, described as one of Germany’s largest owner-managed diagnostic labs [Analytica World, Jan 2025]. The collaboration is focused on co-developing and implementing LIMAA’s platform for routine use in Labor Becker’s pathology laboratory. While the commercial terms are not disclosed, the partnership moves the technology from academic prototype toward a real-world clinical environment, tackling practical challenges of scalability and integrated diagnostics.
The company has also garnered support from established programs in the tech and research ecosystem. It is a member of the NVIDIA Inception program for AI startups and the BIH Digital Health Accelerator, and it is described as a spin-off from Charité - Universitätsmedizin Berlin, a leading European university hospital [LIMAA Technologies, Feb 2024][BioCampus Cologne, retrieved 2026]. This academic pedigree is reflected in its leadership.
The Team Behind the Tissue
The founding team blends scientific and operational expertise, anchored in the Berlin medical research scene. The leadership structure includes:
Co-Founder & Managing Director | 1 | Role
Co-Founder & Head of R&D | 1 | Role
Head of MA & SA and Pathology | 1 | Role
Chairman of the Board | 1 | Role
- Fabian Mohr serves as co-founder and managing director, overseeing business development, fundraising, and company building [LinkedIn, retrieved 2026].
- René Hägerling, a co-founder and head of R&D, leads the scientific development [LIMAA Technologies, retrieved 2026].
- Camila Tomikawa, a co-founder, holds the role of Head of MA & SA (Medical Affairs & Scientific Affairs) and Pathology, bridging clinical and regulatory needs [LinkedIn, retrieved 2026].
- Prof. Dr. med. Jörg Felix Debatin, a physician and former hospital CEO, was appointed Chairman of the Board, lending seasoned medical leadership and governance [LinkedIn, retrieved 2026].
The Road to Regulation and Revenue
The path forward for LIMAA is defined by significant, sequential milestones. The partnership with Labor Becker provides a crucial test bed, but the company’s ambitions are pinned on achieving regulatory clearance as a medical device, a process that will require robust clinical validation. Public details on funding are sparse, with records indicating an early grant from Freie Universität Berlin but no detailed disclosure of institutional venture rounds [Tracxn, 2025]. The next twelve months will likely focus on advancing the prototype through the partnership, gathering the data needed for regulatory submissions, and securing the larger funding round necessary to support that costly process.
The competitive landscape in digital pathology is crowded with companies focusing on slide scanners and AI-based image analysis. LIMAA’s most direct competition may come from firms like NaturalAntibody, though LIMAA’s integrated, tissue-preserving approach carves out a distinct niche. The risks are substantial and familiar in medtech:
- Regulatory hurdling. Achieving CE Mark or FDA clearance for a novel, fully automated diagnostic system is a multi-year, capital-intensive endeavor with no guaranteed outcome.
- Clinical adoption. Even with clearance, convincing pathologists to shift from a century-old, trusted manual process to an automated 3D digital workflow requires demonstrating unambiguous improvements in diagnostic accuracy or workflow efficiency.
- Commercial scale. The integrated hardware-software model implies a high cost of goods and a complex sales cycle targeting large labs and hospital networks.
The company’s answer to these challenges appears to be its deep partnership model, aiming to build the product with and for a leading lab like Labor Becker, thereby de-risking both development and initial adoption.
The Patient in the Picture
For patients facing a cancer diagnosis, the stakes of this technological shift are tangible. The current standard of care often involves a biopsy, followed by a days-long wait while the tissue is processed, sectioned, stained, and analyzed on slides. If the initial tests are inconclusive or if the tumor profile suggests the need for genomic testing, a second, invasive biopsy may be required because the original sample is consumed. LIMAA’s vision is of a future where a single biopsy can yield a comprehensive 3D diagnostic readout and still leave the tissue viable for the advanced molecular profiling that guides modern, personalized therapy. It’s a bet on making the diagnostic journey less invasive, more informative, and ultimately more humane for the patient waiting for answers.
Sources
- [LIMAA Technologies, retrieved 2026] LIMAA Technologies | Fully automated tissue-preserving digital histopathology | https://www.limaa-technologies.com/
- [LinkedIn, retrieved 2026] LIMAA Technologies | https://linkedin.com/company/limaa-technologies
- [Analytica World, Jan 2025] LIMAA Technologies and Labor Becker announce strategic partnership | https://www.analytica-world.com/en/news/1185418/limaa-technologies-and-labor-becker-announce-strategic-partnership.html
- [NANOBODIES-Online, retrieved 2026] LIMAAbodies are in-house developed and validated polyclonal nanobodies | https://www.nanobodies-online.com/
- [Datamintelligence.com, Jun 2024] LIMAA launches nanobody web shop | https://www.datamintelligence.com/
- [LIMAA Technologies, Feb 2024] LIMAA joins NVIDIA Inception Program | http://limaa-technologies.com/news/wmogkqnw5qlvw6gol24odc56g18cmy
- [BioCampus Cologne, retrieved 2026] LIMAA Technologies company profile | https://www.biocampuscologne.de/en/companies/limaa-technologies
- [Tracxn, 2025] LIMAA Technologies - Funding & Investors | https://tracxn.com/d/companies/limaa-technologies/__TyGc8eH49aJJ1g189uJz-dh4tKLeQ2OHeuHQm_45WKo/funding-and-investors